Print page   Email page   Download PDF   
« Previous Release | Next Release »

NeurogesX to Present at Lazard Capital Markets 8th Annual Healthcare Conference

SAN MATEO, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at Lazard Capital Markets 8th Annual Healthcare Conference to be held November 15-16, 2011, at the Pierre Hotel in New York, NY. Mr. DiTonno, as well as Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions and participate in one-on-one meetings with investors.

The presentation will be webcast live and archived for 90 days on the investor relations section of NeurogesX' website at www.neurogesx.com.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq:NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. The Company has submitted a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated peripheral neuropathy (HIV-PN), also known as HIV-associated neuropathy (HIV-AN) and HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed one Phase 2 study in PHN patients and three Phase 1 studies.

The Company's early-stage pipeline includes pre-clinical compounds which include a number of prodrugs of acetaminophen. The Company has evaluated certain of these compounds in vitro and in vivo.

CONTACT: NeurogesX, Inc.

         Stephen Ghiglieri

         Chief Financial Officer

         (650) 358-3310



         The Ruth Group

         Stephanie Carrington (investors)

         (646) 536-7017

         scarrington@theruthgroup.com



         Victoria Aguiar (media)

         (646) 536-7013

         vaguiar@theruthgroup.com

News Provided by Acquire Media

Close window | Back to top